Shares of Mednax, Inc (NYSE:MD) have been given a consensus recommendation of “Hold” by the fifteen research firms that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and one has issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $62.38.
Several brokerages have recently issued reports on MD. Zacks Investment Research upgraded shares of Mednax from a “sell” rating to a “hold” rating in a report on Wednesday, April 19th. Jefferies Group LLC reiterated a “hold” rating and issued a $58.00 price target on shares of Mednax in a report on Wednesday, April 26th. Bank of America Corporation cut shares of Mednax from a “buy” rating to an “underperform” rating in a report on Thursday, May 4th. TheStreet cut shares of Mednax from a “b-” rating to a “c+” rating in a report on Tuesday, May 16th. Finally, Stifel Nicolaus cut their price target on shares of Mednax from $65.00 to $58.00 and set a “hold” rating on the stock in a report on Thursday, May 25th.
Shares of Mednax (MD) opened at 42.93 on Monday. The firm’s 50-day moving average is $53.67 and its 200-day moving average is $61.14. Mednax has a 12-month low of $41.52 and a 12-month high of $72.13. The company has a market capitalization of $3.96 billion, a price-to-earnings ratio of 13.67 and a beta of 0.40.
Mednax (NYSE:MD) last issued its quarterly earnings results on Friday, July 28th. The company reported $0.85 EPS for the quarter, beating analysts’ consensus estimates of $0.81 by $0.04. Mednax had a net margin of 8.78% and a return on equity of 11.89%. The business had revenue of $843 million for the quarter, compared to analysts’ expectations of $849.49 million. During the same period last year, the business earned $1.03 earnings per share. The business’s quarterly revenue was up 9.2% on a year-over-year basis. On average, equities analysts predict that Mednax will post $3.31 EPS for the current year.
In other news, Director Md Pascal J. Goldschmidt sold 1,969 shares of Mednax stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $57.57, for a total value of $113,355.33. Following the completion of the transaction, the director now owns 18,072 shares of the company’s stock, valued at approximately $1,040,405.04. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Joseph M. Calabro sold 23,327 shares of Mednax stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $55.00, for a total value of $1,282,985.00. Following the completion of the transaction, the insider now directly owns 296,379 shares of the company’s stock, valued at approximately $16,300,845. The disclosure for this sale can be found here. Company insiders own 2.40% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its position in shares of Mednax by 5,766.0% in the first quarter. BlackRock Inc. now owns 8,229,340 shares of the company’s stock worth $570,952,000 after buying an additional 8,089,052 shares during the period. Thompson Siegel & Walmsley LLC raised its position in shares of Mednax by 95.9% in the second quarter. Thompson Siegel & Walmsley LLC now owns 2,170,741 shares of the company’s stock worth $131,048,000 after buying an additional 1,062,584 shares during the period. Balyasny Asset Management LLC raised its position in shares of Mednax by 8,590.5% in the second quarter. Balyasny Asset Management LLC now owns 1,060,247 shares of the company’s stock worth $64,007,000 after buying an additional 1,048,047 shares during the period. Schroder Investment Management Group raised its position in shares of Mednax by 144.1% in the first quarter. Schroder Investment Management Group now owns 1,734,697 shares of the company’s stock worth $120,458,000 after buying an additional 1,024,048 shares during the period. Finally, Longview Partners Guernsey LTD raised its position in shares of Mednax by 27.4% in the first quarter. Longview Partners Guernsey LTD now owns 4,555,631 shares of the company’s stock worth $316,070,000 after buying an additional 980,081 shares during the period.
About Mednax
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.
